Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Fred Saad, MD, discusses results from the phase 3 ARANOTE trial which assessed the efficacy and tolerability of adding darolutamide to androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...
According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.
According to updated data from the phase 2 PHAROS trial, encorafenib plus binimetinib showed prolonged efficacy, particularly among treatment-naïve patients, for BRAF V600E-mutant metastatic non-small cell lung cancer.
Georgina Long, MD, PhD, discusses updated pooled analysis results from the International Neoadjuvant Melanoma Consortium which identified that neoadjuvant immunotherapy extends survival in patients with advanced melanoma.
Georgina Long, MD, PhD, discusses updated pooled analysis results from the International Neoadjuvant Melanoma Consortium which identified that neoadjuvant immunotherapy extends survival in patients with advanced melanoma.
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to exploratory results from the phase 3 KRYSTAL-12 trial, adagrasib improved efficacy outcomes among patients with previously treated KRAS G12C-mutated advanced non-small cell lung cancer, regardless of the presence of baseline...
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
According to updated results from the CheckMate 77T study, nivolumab sustained clinical benefit among patients with resectable non-small cell lung cancer.
Jean-Yves Blay, MD, PhD, discusses results from the LENVAGIST study which assessed the clinical efficacy of lenvatinib among patients with advanced gastrointestinal stromal tumors after tyrosine kinase inhibitor failure.
Jean-Yves Blay, MD, PhD, discusses results from the LENVAGIST study which assessed the clinical efficacy of lenvatinib among patients with advanced gastrointestinal stromal tumors after tyrosine kinase inhibitor failure.
Sheela Rao, MBBS, MD, discusses results from the phase 3 POD1UM-303/InterAACT 2 study which showed encouraging efficacy with retifanlimab added to standard of care chemotherapy in patients with locally recurrent or metastatic squamous cell...
Sheela Rao, MBBS, MD, discusses results from the phase 3 POD1UM-303/InterAACT 2 study which showed encouraging efficacy with retifanlimab added to standard of care chemotherapy in patients with locally recurrent or metastatic squamous cell...
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
Results from the phase 2 GALAXIES Lung-201 study show the addition of belrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The NIAGARA trial showed that durvalumab plus neoadjuvant chemotherapy improved EFS and OS compared to neoadjuvant chemotherapy alone in patients with muscle-invasive bladder cancer.
The KEYNOTE-522 trial demonstrated a statistically significant and clinically meaningful improvement in OS with the addition of pembrolizumab to neoadjuvant chemotherapy for patients with high-risk, early-stage triple-negative breast cancer.
The KEYNOTE-522 trial demonstrated a statistically significant and clinically meaningful improvement in OS with the addition of pembrolizumab to neoadjuvant chemotherapy for patients with high-risk, early-stage triple-negative breast cancer.
Results from the phase 3 HypoG-01 trial show hypofractionated locoregional radiation therapy is non-inferior to normofractionated radiation therapy in terms of arm lymphedema risk in early breast cancer and did not lead to unfavorable study...
Results from the phase 3 HypoG-01 trial show hypofractionated locoregional radiation therapy is non-inferior to normofractionated radiation therapy in terms of arm lymphedema risk in early breast cancer and did not lead to unfavorable study...
Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...
Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Pembrolizumab plus chemoradiotherapy significantly improves OS compared to placebo plus chemoradiotherapy in patients with high-risk, locally advanced cervical cancer, according to a second interim analysis from the phase 3...
Pembrolizumab plus chemoradiotherapy significantly improves OS compared to placebo plus chemoradiotherapy in patients with high-risk, locally advanced cervical cancer, according to a second interim analysis from the phase 3...
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
The LEAP-012 trial met its primary end point demonstrating a statistically significant and clinically meaningful improvement in PFS with the addition of lenvatinib plus pembrolizumab to TACE for patients with intermediate-stage hepatocellular...
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Findings from the phase 3 PEACE-3 trial demonstrate the addition of 6 cycles of Ra223 to enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer significantly improves radiological PFS vs enzalutamide alone.
Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.
Lothar Bergmann, MD, discusses results from the phase 2 SUNNIFORECAST trial which assessed the efficacy of combination immunotherapy in patients with advanced non-clear cell renal cancers.
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Filippo Piertrantonio, MD, discusses results from the OrigAMI-1 study, which determined that amivantamab combined with FOLFOX or FOLFIRI demonstrates antitumor activity in patients with RAS/RAF-wild type metastatic colorectal cancer.
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
Nicolas Girard, MD, PhD, discusses results from the phase 2 RELATIVITY-104 study which demonstrated clinical benefit in adding relatlimab to first-line nivolumab plus platinum-doublet chemotherapy among patients with advanced or recurrent...
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
According to primary analysis results from the phase 3 ENGOT-Ov41/GEICO 69-O/ANITA study, the addition of atezolizumab to chemotherapy and maintenance niraparib did not significantly improve progression-free survival (PFS) or objective...
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.
Mary McCormack, MD discusses results from the phase 3 GCIG INTERLACE study evaluating the addition of induction chemotherapy to standard-of-care chemoradiation among patients with advanced cervical cancer.
Mary McCormack, MD discusses results from the phase 3 GCIG INTERLACE study evaluating the addition of induction chemotherapy to standard-of-care chemoradiation among patients with advanced cervical cancer.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
According to pathologic response and exploratory analyses from the SWOG S1801 study, treatment with neo/adjuvant pembrolizumab demonstrated promising response rates among patients with advanced, resectable melanoma.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
For patients with oligometastatic head and neck cancer, the omission of chemotherapy in the frontline setting resulted in lower toxicity rates while maintaining survival rates and quality of life, according to a phase 2 study.
Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...
Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to results from AIN-HN study, tipifarnib is safe, tolerable, and demonstrated anti-tumor activity n later-line settings among patients with HRAS-mutated recurrent or metastatic head and neck squamous cell carcinoma who had received...
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
According to data from the phase 3 NRG-GY004 trial, olaparib with or without cediranib did not improve overall survival when compared with standard of care for patients with platinum-sensitive, relapsed ovarian cancer.
Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...
Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...
Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...
Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
According to results from the phase 3 FLAMES study, maintenance senaparib in the first-line setting significantly reduced the risk of progression or death among patients with newly diagnosed, stage 3 to 4 high-grade serous or endometrioid...
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...
Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...
Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...
At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.
At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to a phase 2b trial, the cancer vaccine MVX-ONCO-1 demonstrated a tolerable safety profile and clinically meaningful prolonged overall survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
According to results from the phase 2 TROPiCS-03 study, sacituzumab govitecan demonstrated efficacy and tolerable safety among patients with heavily pretreated, relapsed or refractory, metastatic or locally advanced head and neck squamous...
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Avelumab plus cetuximab exhibited high clinical activity and tolerable safety among patients with advanced, unresectable cutaneous squamous cell carcinoma, according to preliminary findings from the phase 2 AliCe study.
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Jean-Pascal Machiels, MD, discusses results from the phase 3 KEYNOTE-412 trial showing the addition of pembrolizumab to chemoradiotherapy is associated with a favorable trend toward improved EFS for patients with locally advanced head and...
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Alvaro Arjona-Sanchez, MD, explains findings from a phase 3 studyshowing HIPEC combined with mitomycin C, administered prior to surgical resection for locally advanced colon cancer, led to an improvement in locoregional control rate.
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Melissa Johnson, MD, discusses an OS update from the POSEIDON trial after a median follow-up of approximately 4 years, showing a durable long-term OS benefit by adding tremelimumab to durvalumab and chemotherapy for patients with metastatic...
Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.
Michel Ducreux, MD, reports results from a phase 3 trial showing FOLFIRINOX chemotherapy yields a significantly longer PFS vs gemcitabine for patients with locally advanced, unresectable pancreatic cancer.
Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...
Stéphane Oudard, MD, reports results from a phase 3 trial demonstrating that an adapted schedule of cabazitaxel reduces neutropenic complications seen in elderly patients with metastatic castration-resistant prostate cancer without...
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.
Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.
Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.
Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.
Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.
Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.
Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.
Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...
In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...
In an analysis of Cohort K from the EV-103 trial evaluating enfortumab vedotin plus pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, did that the combination therapy have an objective...
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Additional analyses from the phase 2 MOUNTAINEER study show that tucatinib monotherapy and tucatinib plus trastuzumab were well-tolerated following crossover among patients with HER2-positive colorectal cancer and the concurrent initiation of...
Additional analyses from the phase 2 MOUNTAINEER study show that tucatinib monotherapy and tucatinib plus trastuzumab were well-tolerated following crossover among patients with HER2-positive colorectal cancer and the concurrent initiation of...
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...
Bernd Kasper, MD, PhD, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors.
Bernd Kasper, MD, PhD, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors.
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
Denis Soulières, MD, discusses long-term follow-up data from the phase 3 KEYNOTE-040 and KEYNOTE-048 clinical trials examining pembrolizumab for patients with head and neck squamous cell carcinoma.
According to phase 3 trial results presented at the 2022 ESMO Congress, atezolizumab in the first line improved survival outcomes for platinum-ineligible patients with NSCLC, compared to chemotherapy.
According to phase 3 trial results presented at the 2022 ESMO Congress, atezolizumab in the first line improved survival outcomes for platinum-ineligible patients with NSCLC, compared to chemotherapy.
According to data presented at the 2022 ESMO Congress, the novel liposome formulation of irinotecan, HR070803, plus 5-FU/LV improved the survival outcomes in patients with locally advanced and metastatic pancreatic cancer when compared to...
According to data presented at the 2022 ESMO Congress, the novel liposome formulation of irinotecan, HR070803, plus 5-FU/LV improved the survival outcomes in patients with locally advanced and metastatic pancreatic cancer when compared to...
A phase 3 study presented at the ESMO Congress found treatment with tumor-infiltrating lymphocytes significantly improves PFS vs ipilimumab in patients with advanced melanoma, including those refractory to anti-PD1 therapy.
A phase 3 study presented at the ESMO Congress found treatment with tumor-infiltrating lymphocytes significantly improves PFS vs ipilimumab in patients with advanced melanoma, including those refractory to anti-PD1 therapy.
Dose-dense adjuvant chemotherapy improved disease-free survival and overall survival when compared to the standard schedule for patients with node-positive breast cancer, according to data from a phase 3 trial presented at the 2022 ESMO...
Dose-dense adjuvant chemotherapy improved disease-free survival and overall survival when compared to the standard schedule for patients with node-positive breast cancer, according to data from a phase 3 trial presented at the 2022 ESMO...
Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.
Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.
Findings from the phase 3 DAWNA-2 trial show adding dalpiciclib to first-line letrozole or anastrozole significantly prolongs PFS in HR-positive, HER2-negative advanced breast cancer.
Findings from the phase 3 DAWNA-2 trial show adding dalpiciclib to first-line letrozole or anastrozole significantly prolongs PFS in HR-positive, HER2-negative advanced breast cancer.
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
In the final overall survival analysis of a phase 3 trial, olaparib plus bevacizumab was found to meaningfully improve overall survival for patients with advanced ovarian cancer and homologous recombination deficiency, with or without tumor...
A phase 2 trial found that preoperative immune checkpoint inhibition with nivolumab plus relatlimab is both safe and feasible for patients with curatively resectable NSCLC.
A phase 2 trial found that preoperative immune checkpoint inhibition with nivolumab plus relatlimab is both safe and feasible for patients with curatively resectable NSCLC.
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
The ATALANTE trial evaluating the addition of atezolizumab to platinum-based chemotherapy plus bevacizumab for platinum-sensitive ovarian cancer failed to meet its coprimary PFS end points, according to data presented at the 2022 ESMO...
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Results from a subgroup analyses of the CROWN trial found first-line lorlatinib offered greater PFS benefit to crizotinib in Asian patients with ALK+ NSCLC.
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
French patients with advanced NSCLC with ALK-positive or ROS1-positive gene rearrangement responded well to Crizotinib, according to real-world data presented at the 2021 ESMO Congress.
Susan Dent, MD, discusses the impact of cardiovascular disease (CVD) and health care utilization (HCU) on patients with HR-positive, HER2-negative, advanced breast cancer receiving endocrine therapy.
Susan Dent, MD, discusses the impact of cardiovascular disease (CVD) and health care utilization (HCU) on patients with HR-positive, HER2-negative, advanced breast cancer receiving endocrine therapy.
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Recent data from the ESMO Congress confirm crizotinib showed greater efficacy than brigatinib for patients with ALK TKI-naïve advanced ALK+ NSCLC.
True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).
True or false: Results from a study presented at the 2021 ESMO Congress showed Vimseltinib did not yield promising antitumor activity in tenosynovial giant cell tumor (TGCT).
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
In a recent study in ALK+ NSCLC, post-brigatinib statuses and TKI therapy was investigated to understand the clinical effects of brigatinib after treatment discontinuation.
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.
According to data presented at the 2021 Virtual ESMO Congress, vimseltinib was well tolerated and demonstrated antitumor activity in patients with TGCT.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
The ESMO-MCBS medical device was evaluated for its ability to assess the magnitude of clinical benefit, quality of life, and outcomes in advanced STS and GIST in; these data were presented at the virtual 2021 ESMO Congress.
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Findings from a recent study were shared at the virtual 2021 ESMO Congress to present identifiable, targetable driver mutations for wild-type mutations in GIST and gain insight into developing corresponding targeted therapies.
Preliminary data from an ongoing phase 1 trial of a KIT-altered melanoma cohort show that ripretinib has a manageable safety profile and demonstrates encouraging efficacy.
Preliminary data from an ongoing phase 1 trial of a KIT-altered melanoma cohort show that ripretinib has a manageable safety profile and demonstrates encouraging efficacy.
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Mature data released from the phase 3 INVICTUS trial yields significantly improved PFS, reductions in disease progression, and clinically meaningful OS improvements in advanced gastrointestinal stromal tumors (GIST), presented at the virtual...
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Abdul Rahman Jazieh, MD, MPH, discusses a study on the prevalence of ALK+ NSCLC in the Middle East and North Africa and the importance of testing, presented at the ESMO 2020 Virtual Congress.
Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.
Study data presented by Pascale Tomasini, MD, and co-investigators at the 2020 ESMO Virtual Congress show that vemurafenib has an important role in the treatment of BRAF V600-mutated nonmelanoma cancers.
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
Real-world study findings show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits in patients with relapsed/refractory MM.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Preliminary safety and efficacy data presented at ESMO 2020 Virtual Congress demonstrate that cosibelimab has a manageable safety profile and meaningful clinical activity in patients with mCSCC.
Among patients with NSCLC receiving gemcitabine-carboplatin chemo, neutropenia may predict OS, according to long-term follow-up data presented at the ESMO 2020 Virtual Congress.
Among patients with NSCLC receiving gemcitabine-carboplatin chemo, neutropenia may predict OS, according to long-term follow-up data presented at the ESMO 2020 Virtual Congress.
